NuriFlex Inc. and LINE Plus Corporation Sign MoU for Central Bank Digital Currency (“CBDC”) Projects
NuriFlex Inc. (“NuriFlex”) announced that it has signed a memorandum of understanding (“MoU”) with LINE Plus Corporation (“LINE”), and the two companies intend to collaborate in the Central Bank Digital Currency (“CBDC”) platform business in various regions, including but not limited to the Caribbean, South America and Africa.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210527005334/en/
One of NuriFlex’s business specialties involves the design and development of a blockchain-based platform to offer digital payment and other services for various industry sectors. NuriFlex is currently participating as a main technical partner for the national health coverage system in Cameroon, known as the UHC Project, and it is in several discussions with other partners in Africa to launch other services based on blockchain technologies.
For the last 20 years, NuriFlex Group has focused on the development of a software platform capable of processing a large volume of data, and implemented such a platform to global utility companies. Combining these experiences with blockchain technology, NuriFlex intends to work with a very reputable global partner, LINE Plus Corporation, on global CBDC projects that require a platform that can handle vast volumes of data.
LINE Plus Corporation, the Korea-based subsidiary of LINE Corporation leading LINE’s global business development, has been researching, developing, and operating blockchain-related services including a CBDC blockchain platform with a dedicated blockchain engineering team. Based on LINE Blockchain technology and experience in participating CBDC projects, LINE aims to provide a blockchain platform solution that is the right fit for each CBDC project.
“We are excited to partner and collaborate with LINE on CBDC Projects. The blockchain technology experience and business development capabilities that NuriFlex and LINE bring together will be a great advantage to successfully accomplish CBDC business opportunities,” said Elizabeth Park, Chief Executive Officer of NuriFlex Inc.
“With NuriFlex’s business experience in the region and LINE’s blockchain technology, we hope to bring financial innovation in the Caribbean, South America and Africa with a CBDC blockchain platform,” said Hongkyu Lee, Lead of Blockchain Lab at LINE Plus Corporation.
About NuriFlex Inc.
NuriFlex Inc. is a digital transformation company that provides convergent solutions to address poor efficiency and improve transactional yields in various industries. NuriFlex Inc. offers robust and reliable products and services based on its core telecommunication & blockchain technologies. Learn more at www.nuriflex.com.
About LINE Plus Corporation
LINE Plus Corporation was established in March 2013 in South Korea as a subsidiary of LINE Corporation. It supports LINE’s global business development with programmers, designers, marketers, sales personnel and PR managers from around the world working together.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005334/en/
Contact information
NuriFlex Inc.
Elizabeth Park, CEO
ir@nuriflex.com
www.nuriflex.com
LINE Plus Corporation
Sun Hwangbo, LINE Global PR
dl_gpr@linecorp.com
www.linepluscorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Caranx Medical announces successful world first robotic assisted transcatheter heart valve implantation in an animal16.4.2024 11:30:00 EEST | Press release
Caranx Medical (‘Caranx’), a French medical device company specializing in the development of autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced the successful world first robotic assisted heart valve (aortic valve) implantation in an animal. The assisted heart valve implantation in the animal was successfully performed by Dr. Stéphane Lopez, Caranx CMO Dr. Eric Sejor, Caranx CTO Pierre Berthet-Rayne and Caranx team. “This groundbreaking achievement is the result of hard teamwork. At Caranx Medical, we are dedicated to improving patients' lives through true innovation. This successful transcatheter robotic aortic valve implantation marks the first step toward a new generation of intelligent robots guided by AI, set to transform healthcare as we know it” says Pierre Berthet-Rayne, PhD, co-founder and CTO of Caranx. “This major medical first lies not only in the technical achievement of Caranx Medical's engine
Arthur D. Little Publishes Human After All – Latest Edition of PRISM Magazine16.4.2024 11:00:00 EEST | Press release
Arthur D. Little (ADL) has published Human After All – the latest edition of its strategy and innovation magazine PRISM. As we enter the era of AI, the first edition of 2024 highlights the importance of taking a human-centric approach to business management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416226137/en/ Arthur D. Little has published Human After All – the latest edition of its strategy and innovation magazine PRISM. (Graphic: Business Wire) The magazine features seven key articles: Optimistic global CEOs focus on people and skills in an AI future - Our lead article shares highlights from the ADL 2024 CEO Insights Study, finding that CEOs are increasingly confident of future economic success. The people-centric lab of the future – how technology and AI can play a key role in driving breakthrough innovation by enabling people to become perfect innovators. The future workforce - Recruiting and retaining vital
Magnesium Capital closes oversubscribed inaugural Fund at €135m hard cap16.4.2024 10:32:00 EEST | Press release
Magnesium Capital, the Energy Transition buyout specialist, is delighted to announce the successful close of its inaugural Fund, Magnesium Capital I, at its hard cap of €135m, exceeding the €100m Fund target. The final close occurred less than a year after the Fund’s first close with Magnesium attracting blue-clip institutional investors from the US, Europe and the UK. Magnesium focuses on profitable European companies with proven technologies or tech-enabled services that are positively impacting the decarbonisation of the production, distribution and consumption of energy. The team has been backing the buyouts of such businesses for a number of years on a direct deal basis. Since inception, Magnesium has completed seven platform investments, signed six follow-on acquisitions and exited two investments for 4.2x gross MOIC. The combined impact of these portfolio companies already directly contributes to the avoidance of over 30 million tonnes of CO2 equivalent per annum. Ian Jones, Man
Money20/20 Europe Unveils 2024 Speaker Lineup Under ‘Human X Machine’ Show Theme16.4.2024 10:00:00 EEST | Press release
Money20/20, the world’s leading fintech show and the place where money does business, unveils its agenda for its upcoming Europe show in Amsterdam, 4-6 June. 350+ speakers are expected to take the stage in Amsterdam this year including C-suite executives from global banks such as Deutsche Bank and ING; fintech players such as Adyen and Revolut, senior representatives from the European Central Bank and the European Commission, and blockchain solution providers such as Ripple. The show promises an amalgamation of expertise, from the Wirecard whistleblower Pav Gill to tech evangelist Prince Constantijn van Oranje-Nassau of the Netherlands. Under the theme of ‘Human X Machine’, Money20/20 Europe 2024 will explore the dynamic relationship between humans and intelligent machines, focusing on how the partnership between artificial and human intelligence will forge a new era in finance. In line with this, Money20/20 Europe also welcomes the CEOs of AI firms including Mistral AI, Datasnipper an
MRM Health Reports Safety and Positive Efficacy Data in Pouchitis in Phase 2a Clinical Study with MH00216.4.2024 10:00:00 EEST | Press release
MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today reports positive topline results from its Phase 2a clinical trial with MH002 in the orphan disease indication Pouchitis. MRM Health’s MH002-PC-201 study was a multi-center, open-label clinical trial in 14 acute Pouchitis (PC) patients at multiple clinical sites in Belgium and Italy. The study was designed to evaluate safety (primary objective), initial efficacy, and mechanistic effects of MH002 over 8 weeks. More information about the trial is available at clinicaltrialsregister.eu. The trial met its primary objective with an excellent safety and tolerability at a fixed dose of 400mg per day over 8 weeks’ administration. Treatment-Emergent Adverse Events (TEAE) reported were predominantly mild and unrelated, and there was no evidence of adverse reactions related to MH002. It also demonstrated initial efficacy in clinically relevant parameters,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom